TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Tables)

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

Intangible assets as of December 31, 2014 and 2013 and the movements for the years then ended are as follows:

						Distributor &
		Patents &				Customer
		Trademarks				Relationships				Totals
*Cost or Deemed Cost*
At December 31, 2012		$	3,851,494			$	1,270,639			$	5,122,133
Additions			-				-				-
Disposals			-				-				-
At December 31, 2013		$	3,851,494			$	1,270,639			$	5,122,133

*Accumulated Amortization*
At December 31, 2012		$	1,158,285			$	1,270,639			$	2,428,924
Amortization Charge			258,572				-				258,572
Disposals			-				-				-
At December 31, 2013		$	1,416,857			$	1,270,639			$	2,687,496

*Net Book Value*
At December 31, 2012		$	2,693,209			$	-			$	2,693,209
At December 31, 2013		$	2,434,637			$	-			$	2,434,637

*Cost or Deemed Cost*
At December 31, 2013		$	3,851,494			$	1,270,639			$	5,122,133
Additions			-				-				-
Disposals			-				-				-
At December 31, 2014		$	3,851,494			$	1,270,639			$	5,122,133

*Accumulated Amortization*
At December 31, 2013		$	1,416,857			$	1,270,639			$	2,687,496
Amortization Charge			258,572				-				258,572
Disposals			-				-				-
At December 31, 2014		$	1,675,429			$	1,270,639			$	2,946,068

*Net Book Value*
At December 31, 2013		$	2,434,637			$	-			$	2,434,637
At December 31, 2014		$	2,176,065			$	-			$	2,176,065

Schedule of Estimated Aggregate Amortization Expense of Fiscal Years

The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows:

Period			Amount
2015			$	258,572
2016			$	258,572
2017			$	258,572
2018			$	258,572
2019			$	258,572